Loading...
•
Sep 30, 2020
Bicycle Q3 2020 Earnings Report
Bicycle Therapeutics reported financial results for the third quarter ended September 30, 2020 and discussed recent corporate updates.
Key Takeaways
Bicycle Therapeutics reported their Q3 2020 financial results, highlighting the initiation of three clinical trials and a strengthened corporate leadership. The company's cash position was $149.8 million as of September 30, 2020.
Initiated three clinical trials of novel Bicycles, including a Phase IIa for BT1718, a Phase I for BT8009, and a Phase II for THR-149.
Cash was $149.8 million at September 30, 2020, including net proceeds from an ATM offering and debt financing.
Corporate leadership was strengthened with key appointments to the Scientific Advisory Board and senior management team.
Company is well-positioned to realize the full potential of its disruptive Bicycle technology.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...